metabolic research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The album received critical acclaim upon release. Tim DiGravina of AllMusic wrote that the album is "every bit as dynamic, thunderous, and accomplished as Relationship of Command, Come on Pilgrim, and Nevermind [...] The mad vocals of Andy Falkous make Black Francis look like a geeky school kid in comparison", ending the review by calling it "a fascinating, addictive album that never grows old, never takes itself too seriously, and never grates despite its absolutely raging dynamics." "At the end of the day, what separates Mclusky Do Dallas from all of the shit being passed off as punk or heavy rock is their sense of humor and their ability to not take themselves seriously" writes Jean-Pierre of Tiny Mix Tapes. Chris Dahlen of Pitchfork wrote that their "infectiously poppy songwriting [...] works to keep the mood varied" given that their "straight-up songs" are "wrack(ed) with nervous energy", calling it "one of the tightest, jumpiest, straight-up rock albums around."
Dogs, the first domesticated animal, have been used in hunting, in security and in warfare, as have horses, pigeons and birds of prey; while other terrestrial and aquatic animals are hunted for sports, trophies or profits. Non-human animals are also an important element of human culture, having appeared in cave arts and totems since the earliest times, and are frequently featured in mythology, religion, arts, literature, heraldry, politics, and sports.
Fumito Ueda (上田 文人, Ueda Fumito; born April 19, 1970) is a Japanese video game designer, game director and visual artist. Ueda is best known as the director and lead designer of Ico (2001) and Shadow of the Colossus (2005) during his tenure at Sony Computer Entertainment's Japan Studio, and The Last Guardian (2016) through his own development company GenDesign. His games have achieved cult status and are distinguished by their usage of minimal plot and scenario using fictional languages, and use of overexposed, desaturated light. He has been described by some as an auteur.
In mid September, the US House of Representatives voted for a third time, to end the war, shortly after a CBO report warned the conflict had already cost at least $38 billion, was depleting defensive missile stockpiles to the point of a five-year rebuild, and would add roughly $3 billion per month while fueling inflation.
Pickford & de Matos (2026) revise the fossil record of at least three assemblages of Old World monkeys from the Humpata Plateau (Angola), including possible record of a mandrill-like monkey from the middle Pliocene assemblage from Tchiua. A study on the composition of the Old World monkey assemblage (dominated by Colobus sp. and Chlorocebus sp.) from the Pleistocene Markaytoli site (Ethiopia) is published by Smail et al. (2026). Pallas (2026) identifies fossil mandibles from the Pleistocene sites Asbole (Ethiopia) and Koobi Fora (Kenya) belonging to members of the tribe Colobini, including a taxon with similarities to members of the genus Colobus and a taxon with similarities to members of the Piliocolobus-Procolobus lineage. Evidence from the study of tooth wear of Theropithecus oswaldi from the Pliocene strata from Makapansgat and from the Pleistocene strata from Swartkrans (South Africa), indicative of different dietary behaviors of Pliocene and Pleistocene members of the species (with the diet of the Pliocene specimens including more mechanically resistant food), is presented by L'Engle Williams, Schmidt & Remy (2026). Hidalgo-Trujillo et al. (2026) report evidence from the study of tooth wear indicative of dietary differentiation of extinct papionins from the Turkana Basin. Evidence of similarity of molar morphology to those of members of the genus Papio, and likely evidence of opportunistic feeding strategies, is reported in a specimen of Paradolichopithecus aff. arvernensis from the Dafnero-3 site (Greece) by Plastiras et al. (2026); Koutalis et al.
Sources: en.wikipedia.org
Mitochondrial disease is a group of genetic disorders caused by mitochondrial dysfunction. Mitochondria are the organelles that generate energy for the cell and are found in every cell of the human body except red blood cells. They convert the energy of food molecules into the ATP that powers most cell functions. Mitochondrial diseases take on unique characteristics both because of the way the diseases are often inherited and because mitochondria are so critical to cell function. A subclass of these diseases that have neuromuscular symptoms are known as mitochondrial myopathies. Additionally, different paradigms like intermittent fasting can improve mitochondrial health and contribute in longevity.
The two substrates of this enzyme are 3-nitropropionic acid and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 3-nitroacrylic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3-nitropropanoate:NADP+ oxidoreductase.
In Canada and the United States, half and half almost always refers to a light cream typically used in coffee. (See above.) The name refers to the liquid's content of half milk and half cream. It is widely available in the United States, both in individual-serving containers and in bulk. It is also used to make ice cream. Non-fat versions of the product are also available, containing corn syrup and other ingredients. This half and half can be also used to make a dirty soda. In addition to the light coffee cream, half and half can refer to other drinks in some regions of the U.S. A half and half of iced tea and lemonade is popular in the Northeastern United States. It consists of one part iced tea, sweetened, unsweetened or both, and one part lemonade served over ice. This drink is also called an Arnold Palmer, named for an American golfer, but that drink more correctly is mostly tea with one-quarter to one-third lemonade. In the Southern United States (specifically the cities of Atlanta and Houston), "half and half" may also refer to a mixture of half sweet and half unsweetened iced tea. Some coffee shops in colder climates serve a half and half drink consisting of half coffee and half hot chocolate, similar to caffè mocha. Half and half might also refer to a flavor of soda that combines the flavors of grapefruit and lemon.
==== Reaction with compounds containing active methylene groups ==== In the presence of alkoxides, reactions of ethylene oxide with compounds containing active methylene group leads to the formation of butyrolactones:
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.